AFT Pharmaceuticals Limited

NZSE AFT.NZ

AFT Pharmaceuticals Limited Revenue for the year ending March 31, 2024: USD 116.81 M

AFT Pharmaceuticals Limited Revenue is USD 116.81 M for the year ending March 31, 2024, a 19.90% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • AFT Pharmaceuticals Limited Revenue for the year ending March 31, 2023 was USD 97.43 M, a 8.26% change year over year.
  • AFT Pharmaceuticals Limited Revenue for the year ending March 31, 2022 was USD 89.99 M, a 14.18% change year over year.
  • AFT Pharmaceuticals Limited Revenue for the year ending March 31, 2021 was USD 78.82 M, a 25.65% change year over year.
  • AFT Pharmaceuticals Limited Revenue for the year ending March 31, 2020 was USD 62.73 M, a 8.61% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
NZSE: AFT.NZ

AFT Pharmaceuticals Limited

CEO Dr. Hartley Atkinson Ph.D.
IPO Date Dec. 21, 2015
Location New Zealand
Headquarters 129 Hurstmere Road
Employees 110
Sector Health Care
Industries
Pharmaceuticals
Description

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

StockViz Staff

January 15, 2025

Any question? Send us an email